ProMIS Operating Cycle from 2010 to 2026

PMN Stock  USD 14.05  0.11  0.78%   
ProMIS Neurosciences Operating Cycle yearly trend continues to be very stable with very little volatility. Operating Cycle is likely to drop to 1,052. During the period from 2010 to 2026, ProMIS Neurosciences Operating Cycle quarterly data regression pattern had sample variance of 1.5 M and median of  1,216. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
1.4 K
Current Value
1.1 K
Quarterly Volatility
1.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check ProMIS Neurosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ProMIS Neurosciences' main balance sheet or income statement drivers, such as Interest Expense of 65.6 K, Total Revenue of 0.0 or Other Operating Expenses of 20.3 M, as well as many indicators such as Price To Sales Ratio of 5.1 K, Dividend Yield of 0.0 or PTB Ratio of 1.63. ProMIS financial statements analysis is a perfect complement when working with ProMIS Neurosciences Valuation or Volatility modules.
  
Build AI portfolio with ProMIS Stock
Check out the analysis of ProMIS Neurosciences Correlation against competitors.
To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.
Evaluating ProMIS Neurosciences's Operating Cycle across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into ProMIS Neurosciences's fundamental strength.

Latest ProMIS Neurosciences' Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of ProMIS Neurosciences over the last few years. It is ProMIS Neurosciences' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ProMIS Neurosciences' overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Pretty Stable
   Operating Cycle   
       Timeline  

ProMIS Operating Cycle Regression Statistics

Arithmetic Mean1,199
Geometric Mean515.39
Coefficient Of Variation100.61
Mean Deviation654.28
Median1,216
Standard Deviation1,207
Sample Variance1.5M
Range5.2K
R-Value(0.17)
Mean Square Error1.5M
R-Squared0.03
Significance0.52
Slope(40.32)
Total Sum of Squares23.3M

ProMIS Operating Cycle History

2026 1051.84
2025 1398.87
2018 1216.41
2017 100.59
2016 1262.24
2014 232.69
2013 1.76

About ProMIS Neurosciences Financial Statements

ProMIS Neurosciences investors utilize fundamental indicators, such as Operating Cycle, to predict how ProMIS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Operating Cycle1.4 K1.1 K

Pair Trading with ProMIS Neurosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.

Moving against ProMIS Stock

  0.51XNCR Xencor IncPairCorr
  0.49GANX Gain TherapeuticsPairCorr
  0.44KURA Kura OncologyPairCorr
  0.43KOD Kodiak SciencesPairCorr
  0.43IMCC Im Cannabis CorpPairCorr
The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.
The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether ProMIS Neurosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProMIS Neurosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Promis Neurosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Promis Neurosciences Stock:
Check out the analysis of ProMIS Neurosciences Correlation against competitors.
To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Will Biotechnology sector continue expanding? Could ProMIS diversify its offerings? Factors like these will boost the valuation of ProMIS Neurosciences. Anticipated expansion of ProMIS directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ProMIS Neurosciences data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(20.00)
Revenue Per Share
0.001
Return On Assets
(0.85)
Return On Equity
(3.56)
ProMIS Neurosciences's market price often diverges from its book value, the accounting figure shown on ProMIS's balance sheet. Smart investors calculate ProMIS Neurosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since ProMIS Neurosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between ProMIS Neurosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProMIS Neurosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.